Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Paltusotine

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Crinetics Submits NDA For Paltusotine For Treatment Of Acromegaly
    Crinetics Submits NDA For Paltusotine For Treatment Of Acromegaly

    26 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/26/2954138/0/en/Crinetics-Submits-New-Drug-Application-for-Paltusotine-for-the-Treatment-of-Acromegaly.html

    GLOBENEWSWIRE
    26 Sep 2024
    Share Share
    Crinetics Positions Paltusotine As Potential Acromegaly First Choice
    Crinetics Positions Paltusotine As Potential Acromegaly First Choice

    03 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/03/2892444/0/en/Crinetics-Presents-New-Data-at-ENDO-2024-that-Increases-Body-of-Evidence-Positioning-Once-Daily-Oral-Paltusotine-as-Potential-First-Choice-Treatment-Option-for-Acromegaly.html

    GLOBENEWSWIRE
    03 Jun 2024
    Share Share
    Crinetics At ENDO On Atumelnant, Paltusotine Programs
    Crinetics At ENDO On Atumelnant, Paltusotine Programs

    08 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/08/2878214/0/en/Crinetics-Pharmaceuticals-to-Present-Advancements-from-Atumelnant-CRN04894-and-Paltusotine-Development-Programs-at-ENDO-2024.html

    GLOBENEWSWIRE
    08 May 2024
    Share Share
    Crinetics Bags Second Phase III Win for Acromegaly, Heads for NDA Submission
    Crinetics Bags Second Phase III Win for Acromegaly, Heads for NDA Submission

    20 Mar 2024

    // BIOSPACE

    https://www.biospace.com/article/crinetics-bags-second-phase-iii-win-for-acromegaly-heads-for-nda-submission-/

    BIOSPACE
    20 Mar 2024
    Share Share
    Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine
    Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine

    12 Mar 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/03/12/2845006/0/en/Crinetics-Announces-Positive-Topline-Results-from-Phase-2-Trial-of-Paltusotine-for-the-Treatment-of-Carcinoid-Syndrome.html

    GLOBENEWSWIRE
    12 Mar 2024
    Share Share
    Crinetics Announces Positive Findings from Open-Label Phase 2 of Paltusotine
    Crinetics Announces Positive Findings from Open-Label Phase 2 of Paltusotine

    18 Dec 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/12/18/2798132/0/en/Crinetics-Announces-Positive-Initial-Findings-from-Ongoing-Open-Label-Phase-2-Study-of-Paltusotine-for-the-Treatment-of-Carcinoid-Syndrome.html

    GLOBENEWSWIRE
    18 Dec 2023
    Share Share